Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
SAB Biotherapeutics ( (SABS) ) has provided an update.
On December 29, 2025, SAB Biotherapeutics, Inc. entered into a new sales agreement with UBS Securities LLC to establish an at-the-market equity offering program allowing the company to issue and sell up to $75 million of its common stock from time to time on Nasdaq at prevailing market prices, with proceeds intended to support its development pipeline and general corporate purposes. This new program, under which SAB will pay UBS up to 3% of gross proceeds per share sale and which either party can terminate on ten days’ notice, follows the company’s December 17, 2025 termination of its prior $20 million at-the-market arrangement with Cantor Fitzgerald & Co., which ended without any associated costs or payments and cleared the way for the larger UBS-led facility.
The most recent analyst rating on (SABS) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on SAB Biotherapeutics stock, see the SABS Stock Forecast page.
Spark’s Take on SABS Stock
According to Spark, TipRanks’ AI Analyst, SABS is a Neutral.
The overall stock score is primarily impacted by significant financial challenges, including declining revenues and negative cash flows. While technical analysis shows bullish momentum, poor valuation metrics and financial performance weigh heavily on the score.
To see Spark’s full report on SABS stock, click here.
More about SAB Biotherapeutics
SAB Biotherapeutics, Inc. is a biotechnology company whose primary activities include the development of a therapeutic pipeline, funded in part through equity offerings of its common stock. The company is listed on the Nasdaq Stock Market and utilizes shelf registration statements and at-the-market equity programs as part of its capital-raising strategy to support pipeline development and general corporate and working capital needs.
Average Trading Volume: 318,432
Technical Sentiment Signal: Buy
Current Market Cap: $180M
For an in-depth examination of SABS stock, go to TipRanks’ Overview page.